Insurance premium growth forecast in real terms...
Category:
Life
Latest
Stalin says LIC website reduced to propaganda tool for Hindi imposition, Corporation resolves technical glitch
M K Stalin,Tamil Nadu Chief Minister LIC has clarified that there...
Prudential launches global AI Lab in Singapore, to improve consumer access to quality healthcare
Anil Wadhwani, Chief Executive Officer, Prudential plc, said:...
Govt readies amendments to GIBNA for insurance PSU privatisation
The NITI Aayog was entrusted with the task of recommending a suitable candidate for privatisation of two public sector banks and one general insurance company. The government think-tank is believed to have suggested the name of United India Insurance to the Core Group of Secretaries on Disinvestment headed by the Cabinet Secretary.
Insurance companies remain prime targets for Private Equity:AM Best
private equity firms also have infused considerable amounts of capital to spur rapid growth—a strategy that insurers do not typically execute well. In the first year of private equity ownership, 38% of companies reported increases of over 20% in capital and surplus, rising to 43% in year No. 2 and 50% in year No. 3.
Covid will be reduced to an endemic in future, zero figure in Delhi unlikely: Experts
Dr Suresh Kumar, medical director of Delhi government-run LNJP Hospital said there will always be a few cases of the virus.
”Zero is an unlikely figure. The virus is mutating and it is difficult to predict it’s future behaviour,” he said.
59 pc men feel work stress taking toll on personal lives: Survey
With the work from the home norm and increased workload, employees are facing challenges with their jobs, which is taking a toll on their mental health and personal lives, the survey has revealed.
The symptoms of the Delta variant appear to differ from traditional COVID symptoms. Here’s what to look out for
While fever and cough have always been common COVID symptoms, and headache and sore throat have traditionally presented for some people, a runny nose was rarely reported in earlier data. Meanwhile, loss of smell, which was originally quite common, now ranks ninth.
Mortality ‘significantly’ increased in 2nd Covid wave in India: study
”The second wave of COVID-19 in India was slightly different in presentation than the first wave, with a younger demography, lesser comorbidities, and presentation with breathlessness in greater frequency,” the study stated.
Covid jabs to key workers, then elderly followed by comorbid people of 24-60 yrs hikes impact: Study
Highlighting the findings of the study, the Indian Council of Medical Research (ICMR) said in low-intensity transmission areas such as sparsely populated areas, vaccinating individuals with comorbidity after key workers and then reaching out to those above 60 years appears to be an elegant public health approach.
People in states with high PM2.5 levels more likely to get COVID-19: Study
Sixteen major cities, including Delhi, Mumbai, Chennai, Bangalore, Kolkata, Pune, Ahmedabad, Varanasi, Lucknow and Surat, reported the highest number of COVID-19 cases, and PM2.5 emissions are also higher in these areas due to fossil fuel-based anthropogenic activities, it said.
PM2.5 refers to fine particles which penetrate deep into the body and fuel inflammation in the lungs and respiratory tract, leading to the risk of having cardiovascular and respiratory problems, including a weak immune system.
Majority of urban unemployed Indians want Job, not cash handout:LSE study says
“Younger individuals, in the bottom half of pre-Covid earnings, experienced higher levels of worklessness,” the authors wrote, based on responses from 4,763 individuals between January and March this year in three lower-income states of Bihar, Jharkhand and Uttar Pradesh.
Final analysis of Covaxin efficacy out; vaccine 65.2 percent effective against Delta variant
Director-General of ICMR, Balram Bhargava said, ”I am delighted to note that Covaxin developed by ICMR and BBIL under an effective public private partnership, has demonstrated an overall efficacy of 77.8 percent in Indias largest COVID phase 3 clinical trial thus far.
He further said Covaxin will not only benefit the Indian citizens but would also immensely contribute to protecting the global community against the deadly SARS-CoV-2 virus.